Parion Lands Monster Deal With Gilead For Cystic Fibrosis Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
With another CF candidate in Phase III, Gilead looks to build a respiratory disease franchise, R&D chief tells “The Pink Sheet” DAILY.
You may also be interested in...
Deal Watch: Pfizer/AstraZeneca Lead Pack Of Takeover Efforts
Pfizer’s new, increased offer for AstraZeneca on May 2 was rejected swiftly by the U.K.’s second-largest pharmaceutical company. But other companies’ acquisitive strategies have been more successful this week, with Forest announcing plans to acquire Furiex, Bristol buying out one-asset biotech iPierian, and Endo nabbing the privately owned Mexican specialty company, Somar.
Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
Exec discusses the therapeutic areas Gilead’s pipeline will focus on in the future, the importance of licensing/acquisition deals and pursuing additional indications for some of the firm’s currently marketed products.
Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
Exec discusses the therapeutic areas Gilead’s pipeline will focus on in the future, the importance of licensing/acquisition deals and pursuing additional indications for some of the firm’s currently marketed products.